Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel — Miquel Bernardo (2025) | RDL Network
Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel
Article 2025 en
Authors
MB
Miquel Bernardo
MD
Marina Díaz‐Marsá
AG
Ana González‐Pinto
Abstract
1 min read
In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.
Sílvia Amoretti, Norma Verdolini, Gisela Mezquida, Francisco Diego Rabelo‐da‐Ponte, Manuel J. Cuesta, Laura Pina‐Camacho, Marta Gómez-Ramiro, Concepción De‐la‐Cámara, Ana González‐Pinto, Covadonga M. Díaz‐Caneja, Iluminada Corripio, Eduard Vieta, Elena de la Serna, Anna Mané, Brisa Solé, André F. Carvalho, Maria Serra‐Navarro, Miquel Bernardo
Marco Solmi, Andréa Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V. Seeman, Christoph U. Correll, André F. Carvalho
Christian Núñez, Christian Stephan‐Otto, Judith Usall, Miquel Bioque, António Lobo, Ana González‐Pinto, Laura Pina‐Camacho, Eduard Vieta, Josefina Castro‐Fornieles, Roberto Rodríguez–Jiménez, Anna Butjosa, Joost Janssen, Bibiana Cabrera, Mara Parellada, Miquel Bernardo, Gisela Mezquida, Sílvia Amoretti, Elisa Rodríguez-Toscano, Yasser Alemán‐Gómez, Eric P. Zorrilla, Sainza García, Concepción De‐la‐Cámara, Fe Barcones,
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Christian Frølund, Angelo Belotti, Albert Oriol, Philippe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.